DOSSIER · UPDATED 18 NOV 2025

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

iovance.com ↗Claim this profile

Founded: 2007
Headcount: 434
Open roles: 38
Last raised: Post Ipo Equity · $211M

SECTION I · THE BRIEF

Inside Iovance Biotherapeutics

Brief #93312Updated 18 NOV 2025SAN CARLOSMEDICAL ORGANIZATIONSPOST IPO EQUITY

Employbl Dossier

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Founded: 2007
Headcount: 434
Open roles: 38
Last raised: Post Ipo Equity · $211M

Section II — RestrictedMembers only

Tech stack (Iovance Biotherapeutics engineering primaries)
Hiring focus this quarter
Interview format & rubric
Comp bands by level
Decision-makers in talent
Recent news & moves

Open Iovance Biotherapeutics brief Sign in

7-day free trial · $25/mo · cancel anytime

TAGS

Categorized in

Company Collections

These are collections Iovance Biotherapeutics is a part of. Click on the collection name to view similar companies.

Iovance Biotherapeutics' Industries

Medical Organizations

Health Care Companies

Biotechnology Companies

Iovance Biotherapeutics' Tech Stack

Amazon Web Services

OPEN ROLES

Hiring at Iovance Biotherapeutics

Current Job Listings

Listing 0 of 38 job openings

LOCATIONS

Where they work

Iovance Biotherapeutics Headquarters Location

825 Industrial Road 4th Floor, San Carlos, CA, 94070

Loading map…

FUNDING

Capital raised

Total Amount Raised: $1,576,400,128

Iovance Biotherapeutics Funding Rounds

Post Ipo Equity
$211,000,000
Feb 20, 2024
Post Ipo Equity
$211,000,000
Feb 19, 2024
Post Ipo Equity
$150,000,000
Jul 10, 2023
Post Ipo Equity
$150,000,000
Jul 9, 2023
Post Ipo Equity
$603,700,000
May 27, 2020
Post Ipo Equity
$603,700,000
May 26, 2020
Post Ipo Equity
$252,200,000
Oct 11, 2018
Post Ipo Equity
$252,200,000
Oct 10, 2018
Post Ipo Equity
$172,500,000
Jan 24, 2018
Post Ipo Equity
$172,500,000
Jan 23, 2018
Post Ipo Equity
$100,000,000
Jun 3, 2016
Post Ipo Equity
$100,000,000
Jun 2, 2016
Post Ipo Equity Investors
Quogue Capital
OrbiMed Advisors
Frazier Management
Broadfin Capital
Post Ipo Equity
$64,000,000
Feb 26, 2015
Post Ipo Equity
$64,000,000
Feb 25, 2015
Post Ipo Equity
$23,000,000
Oct 31, 2013
Post Ipo Equity
$23,000,000
Oct 30, 2013
IPO
Unknown
Aug 13, 2010
IPO
Unknown
Jan 1, 2010

Funding info provided by Diffbot.

EMPLOYEE REVIEWS

On the ground at Iovance Biotherapeutics

Iovance Biotherapeutics Reviews

Based on 0 reviews

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Iovance Biotherapeutics.